Bioanalytical Method Validation of Dasatinib in Human Plasma Using the LC-MS/MS Method
Abstract:
A sensitive and selective LC-MS/MS method for estimation of Dasatinib in K2EDTA human plasma was developed and validated. The concentration range was 1.0 ng/mL to 800.0 ng/mL. Sample preparation and analysis are carried out for Dasatinib as analyte using Dasatinib D8 as internal standard. Analyte was separated by reverse phase chromatography using Thermo Hypurity C8 100*4.6 mm Column. Electro spray Ionization detections of Dasatinib, Dasatinib D8 were carried out with multiple reaction monitoring of m/z 488.1/401.1, 496.1/406.1 respectively in positive ion mode [M+H] + using a triple quadruple mass spectrometer. The retention time for Dasatinib and Dasatinib D8 was 1.36 Minutes ± 30 seconds and 1.37 Minutes ± 30 seconds respectively with a total run time of 2.50 minutes. No interfering peaks or matrix effects were observed. This article provides the results of standard curves, quality control samples, recovery, and stability experiments. The LC-MS/MS method for the determination of Dasatinib in human plasma has specifications for sensitivity, reproducibility and accuracy.References:
[1]. American Cancer Society. Key statistics for
acute lymphocytic leukemia. 2024 Jan 17 [cited 2024 Nov 5]. Available from: https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/key-statistics.html
[2]. Apotex Corp. Apotex Corp. is the first
generic manufacturer to launch dasatinib tablets in the United States. 2024 Sep
5 [cited 2024 Nov 5]. Available from: https://www.apotex.com/us/about-us/news/2024/09/05/apotex-corp.-is-the-first-generic-manufacturer-to-launch-dasatinib-tablets-in-the-united-states
[3]. Chokshi A, Gajjar A, Bhanushali P, Desai P.
Quantification of antileukemic drug dasatinib in human plasma: application of a
sensitive liquid chromatographic method. J Chem Metrol. 2021;15(2):152‑162.
Available from: https://www.acgpubs.org/doc/20211226124933A5-64-JCM-2108-2174.pdf
[5]. DrugBank. Dasatinib (DB01254). 2024 [cited
2025 Sep 29]. Available from: https://go.drugbank.com/drugs/DB01254
[6]. Drugs.com. Availability of generic Sprycel.
2024 Nov 6 [cited 2024 Nov 6]. Available from: https://www.drugs.com/availability/generic-sprycel.html
[7]. Elsevier. Tyrosine kinase inhibitor.
ScienceDirect. [cited 2024 Oct 27]. Available from: https://www.sciencedirect.com/topics/chemistry/tyrosine-kinase-inhibitor#chapters-articles
[10]. International Council for Harmonisation.
ICH guideline M10: bioanalytical method validation and study sample analysis.
2022 May 24 [cited 2024 Nov 20]. Available from: https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf
[11]. National Center for Biotechnology
Information. PubChem Compound Summary for CID 3062316, Dasatinib. 2025 [cited
2025 Sep 29]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Dasatinib
[12]. National Cancer Institute. Cancer Stat
Facts: Leukemia — Chronic Myeloid Leukemia (CML). [cited 2024 Nov 5]. Available
from: https://seer.cancer.gov/statfacts/html/cmyl.html?form=MG0AV3
[13]. Phenomenex. Sample preparation reference
manual and user’s guide. 2022 [cited 2024 Nov 20]. Available from: https://www.phenomenex.com/documents/sample-preparation-reference-manual--users-guide
[14]. Saraner N, Karagoz A, Guney B, Saglam O.
Determination of dasatinib in human plasma using liquid chromatography‑tandem
mass spectrometry. Int J Anal Bioanal Methods. 2019;1(1):002. Available from: https://vibgyorpublishers.org/content/ijabm/ijabm-1-002.pdf
[15]. Shodex HPLC Columns. Lesson 3:
partition/adsorption chromatography. [cited 2024 Nov 20]. Available from: https://shodexhplc.com/lessons/lesson-3-partitionadsorption-chromatography/
[16]. Souza ID, Queiroz MEC. Innovations and
strategies of sample preparation techniques to reduce matrix effects during
LC–MS/MS bioanalysis. LCGC Suppl. 2021;39(s11):21‑3. Available from: https://www.chromatographyonline.com/view/innovations-and-strategies-of-sample-preparation-techniques-to-reduce-matrix-effects-during-lc-ms-ms-bioanalysis
[17]. Supriya V, Shakirunisa M, Santhi OK, Rani
TS, Swathi CA, Padmalatha K. A review on bioanalytical method development and
validation. Indo Am J Pharm Sci. 2021;8(5):210‑25. Available from: https://www.iajps.com/wp-content/uploads/2021/05/25.IAJPS25052021.pdf
[18]. U.S. Food and Drug Administration. Label
for drug SPRYCEL® (dasatinib) (NDA 021986, Supplement 028). 2024 [cited 2024
Nov 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021986s028lbl.pdf
[19]. Winslow T. Acute lymphoblastic leukemia
treatment. National Cancer Institute. 2024 [cited 2024 Nov 20]. Available from:
https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq
